Staphylococcus Aureus Infection Clinical Trial
NCT number | NCT01879761 |
Other study ID # | 13-0491 |
Secondary ID | |
Status | Active, not recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 2013 |
Est. completion date | June 2024 |
Verified date | January 2024 |
Source | University of Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
Status | Active, not recruiting |
Enrollment | 102 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least one blood culture positive for S. aureus - Patients aged =18 years - At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are: - Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F) - Heart rate greater than 90 beats per minute - Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg - WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms) Exclusion Criteria: - Sequential Organ Failure Assessment (SOFA) score > 12 on day of positive blood cultures - Survival expected to be < 7 days from positive blood cultures |
Country | Name | City | State |
---|---|---|---|
United States | University of Chicago Hospital | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mortality | 0-90 days | ||
Primary | HLA-DR and cytokines | Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA. | 0-30 days | |
Secondary | New Infections | 0-90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04210505 -
Nasal Decolonization of Dialysis Patients Noses
|
Phase 4 | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02804711 -
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282605 -
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT06317688 -
Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis
|
Phase 1 | |
Withdrawn |
NCT02741869 -
Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients
|
N/A | |
Completed |
NCT03966040 -
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 1 | |
Completed |
NCT04803708 -
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05117398 -
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
|
Phase 3 | |
Not yet recruiting |
NCT06456424 -
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
|
Phase 1/Phase 2 | |
Completed |
NCT02820883 -
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 0 | |
Completed |
NCT01375621 -
Livestock Contact and MRSA in Rural Areas
|
||
Recruiting |
NCT00532324 -
Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns
|
N/A | |
Completed |
NCT04503252 -
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
|
||
Recruiting |
NCT06368856 -
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
|
Phase 1 | |
Not yet recruiting |
NCT05899140 -
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT01792804 -
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
|
Phase 3 | |
Enrolling by invitation |
NCT04897971 -
Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
|
||
Completed |
NCT00572910 -
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
|
Phase 2 |